Friday, July 7, 2017
Recombinant Factor IX Products
David F. Nickel
Foster, Murphy, Altman, & Nickel
Bioverativ Inc., Bioverativ Therapeutics Inc., and Bioverativ U.S. LLC
Letter to Lisa R. Barton, Secretary, USITC; requesting that the Commission conduct an investigation under section 337 of the Tariff Act of 1930, as amended, regarding Certain Recombinant Factor IX Products. The proposed respondents are CSL Behring LLC, King of Prussia, Pennsylvania; CSL Behring GmbH, Germany; and CSL Behring Recombinant Facility AG, Switzerland.